Literature DB >> 10985875

Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram): a case study.

E Freye1, J Levy.   

Abstract

We report on a patient who had taken the centrally acting analgesic tramadol for over 1 year. The compound had proven to be sufficient to treat her painful episodes related to fibromyalgia. Due to lack of supply while being on a trip, intake of the drug was stopped abruptly, resulting in the development of classical abstinence-like symptoms within 1 week. Abstinence-like symptoms consisted of restlessness and insomnia for which the benzodiazepine lorazepam was given. Diarrhoea and abdominal cramps were treated with the peripherally active opioid loperamide, while bouts of cephalgia were treated with sumatriptan. Diffuse musculoskeletal-related pain and restless leg syndrome (RLS) were treated with dextromethorphan. All these different medications proved to be efficacious as they resulted in the cessation of symptoms. Within 1 week symptoms ceased and the patient regained her normal activities without any sequelae. Although tramadol is considered a non-habit- and non-dependence-forming analgesic, abstinence symptoms are likely to develop following abrupt cessation of intake, especially when the compound had been taken over 1 year. Therefore patients should be advised of such an effect whenever they decide to stop intake or their physician is planning to switch to another medication. To avoid abstinence-like symptoms doses should be slowly tapered down.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985875     DOI: 10.1053/eujp.2000.0187

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  13 in total

Review 1.  Tramadol for the management of premature ejaculation: a timely systematic review.

Authors:  E W Kirby; C C Carson; R M Coward
Journal:  Int J Impot Res       Date:  2015-05-14       Impact factor: 2.896

2.  All-Cause Mortality Associated with Tramadol Use: A Case-Crossover Study.

Authors:  Sohyun Jeong; Ha Jin Tchoe; Junqing Li; Ju-Young Shin
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606

3.  Physical dependence potential of daily tramadol dosing in humans.

Authors:  Ryan K Lanier; Michelle R Lofwall; Miriam Z Mintzer; George E Bigelow; Eric C Strain
Journal:  Psychopharmacology (Berl)       Date:  2010-06-30       Impact factor: 4.530

4.  Abuse liability and reinforcing efficacy of oral tramadol in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Anthony J Siegel; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2012-10-23       Impact factor: 4.492

Review 5.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

Review 6.  Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol.

Authors:  David H Epstein; Kenzie L Preston; Donald R Jasinski
Journal:  Biol Psychol       Date:  2006-02-23       Impact factor: 3.251

Review 7.  Evaluation of treatments for myofascial pain syndrome and fibromyalgia.

Authors:  Nathan J Rudin
Journal:  Curr Pain Headache Rep       Date:  2003-12

8.  Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.

Authors:  Michelle R Lofwall; Shanna Babalonis; Paul A Nuzzo; Anthony Siegel; Charles Campbell; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2013-06-04       Impact factor: 4.492

9.  Tramadol dependence: a case series from India.

Authors:  Siddharth Sarkar; Naresh Nebhinani; Shubh M Singh; Surendra K Mattoo; Debasish Basu
Journal:  Indian J Psychol Med       Date:  2012-07

10.  Psychosis following Tramadol Withdrawal.

Authors:  Ghodratolah Rajabizadeh; Ali Kheradmand; Mansoureh Nasirian
Journal:  Addict Health       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.